Eiger appoints David Apelian as permanent CEO; grants 750,000 stock options

Eiger BioPharmaceuticals, Inc.

David Apelian, Interim CEO since Dec 2022, named CEO effective June 28, 2023; remains on Board.
Annual salary of $650,000 with bonus target of 60% of base salary.
Grant of nonstatutory stock options for 750,000 shares vesting monthly over 48 months.
Severance includes 12 months salary plus prorated target bonus on termination without cause or for good reason.
Change-in-control severance: 18 months salary, full equity acceleration, COBRA coverage up to 18 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Apelian

Chief Executive Officer

Eiger BioPharmaceuticals, Inc.

Effective: 2023-06-28
Filed: June 30, 2023, 7:59 PM ET

On June 28, 2023, the Board of Directors (the “ Board ”) of Eiger BioPharmaceuticals, Inc. (the “ Company ”) appointed David Apelian, the Company’s current Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Apelian was appointed as Chief Executive Officer at Eiger BioPharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On June 28, 2023, the Board of Directors (the “ Board ”) of Eiger BioPharmaceuticals, Inc. (the “ Company ”) appointed David Apelian, the Company’s current Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-180435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.